BioWorld

July 30, 2008

Rebounding Amgen Trumps Q2 Estimates Despite Profit Decline

Amgen Inc.'s second-quarter earnings outstripped Wall Street expectations and sent shares rising for the second day in a row, signaling a much-needed upturn following a year and a half of negative ESA headlines. (BioWorld Today) Read More

FDA Panel Backs Approval of Roche IL-6 Arthritis Drug

Intercept Gets $25M for Bile Acid Trials

Celator Raises $22.5M for CombiPlex Products Pipeline

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 21, 2026.

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

LIT-002 is strong candidate for autism and neuropathic pain

BioWorld Science

Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

New biomarker may improve RSV drug screening

BioWorld

Respiratory syncytial virus (RSV) infection is responsible for 3.2 million hospital admissions and about 118,000 deaths in children under 5 years of age. The...